European Vaccine Initiative
The European Vaccine Initiative (EVI) is leading European efforts to develop effective, accessible, and affordable vaccines against diseases of poverty. EVI’s vision is 'a world free of the intolerable burden of diseases of poverty within the coming decades'.
Aeras Global TB Vaccine Foundation
Aeras Global TB Vaccine Foundation was founded in 1997 to help develop new concepts and tools to control the global TB epidemic. Today the organization focuses solely on developing new vaccines against TB and ensuring their availability to all who need them.
TuBerculosis Vaccine Initiative
TBVI is an independent non-profit foundation that facilitates the development of new vaccines to protect future generations against tuberculosis.
TBVI financially supports and brings expertise to an integrated network of over 40 universities, institutes and industries to develop more effective, safe vaccines that will be globally accessible and affordable. Research conducted by our mostly European based network has already resulted in promising vaccine discoveries.
PATH Malaria Vaccine Initiative
The PATH Malaria Vaccine Initiative (MVI) is a focused vaccine development program created in 1999 through a grant from the Bill & Melinda Gates Foundation.
MVI's mission is to accelerate the development of promising malaria vaccines and ensure their availability and accessibility in the developing world.
International AIDS Vaccine Initiative
IAVI is a global not-for-profit, public-private partnership working to accelerate the development of a vaccine to prevent HIV infection and AIDS. Founded in 1996, IAVI researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe.
Institute for OneWorld Health
OneWorld Health directs a worldwide effort to uncover, research, and develop new medicines for neglected infectious diseases.
Drugs for Neglected Diseases initiative
In 2003, seven organisations from around the world joined forces to establish DNDi: five public sector institutions – the Oswaldo Cruz Foundation from Brazil, the Indian Council for Medical Research, the Kenya Medical Research Institute, the Ministry of Health of Malaysia and France’s Pasteur Institute; one humanitarian organisation, Médecins sans Frontières (MSF); and one international research organisation, the UNDP/World Bank/WHO’s Special Programme for Research and Training in Tropical Diseases (TDR), which acts as a permanent observer to the initiative.
DNDi doesn’t conduct research and scientific work to develop drugs itself. Instead, it capitalizes on existing, fragmented R&D capacity, especially in the developing world, and complements it with additional expertise as needed. This “virtual organization” model helps cut costs.
Medicines for Malaria Venture
A nonprofit organization created to discover, develop and deliver new antimalarial drugs through effective public-private partnerships.
Global Alliance for TB Drug Development
The Global Alliance for TB Drug Development (TB Alliance) is a not-for-profit, product development partnership accelerating the discovery and development of new tuberculosis (TB) drugs that will shorten treatment, be effective against susceptible and resistant strains, be compatible with antiretroviral therapies for those HIV-TB patients currently on such therapies, and improve treatment of latent infection.
European and Developing Countries Clinical Trials Partnerhship
The European & Developing Countries Clinical Trials Partnership (EDCTP) was created in 2003 as a European response to the global health crisis caused by the three main poverty-related diseases of HIV/AIDS, malaria and tuberculosis. These diseases account for over 6 million deaths each year, and the numbers are growing. Sub-Saharan Africa is the world's worst-affected region where besides ravaging lives, they impede development and cause poverty.
Partnerships for product development
co-operation for neglected diseases
| Powered by
and designed by